Enfusion, Inc. EBITDA margin
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
| EBITDA margin | 25.5% | 10.5% | (243.4%) | (3.7%) | 12.6% | 3.1% |
Enfusion, Inc. (ENFN) EBITDA margin comparison analysis
General
LTM EBITDA margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
ENFN key stats
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
% growth | 59.0 0.0% | 79.6 34.8% | 111.7 40.4% | 150.3 34.6% | 174.5 16.1% | 201.6 15.5% |
| Cost of Goods Sold (COGS) | 17.0 | 21.4 | 31.8 | 47.1 | 57.6 | 64.9 |
% margin | 42.1 71.3% | 58.2 73.2% | 79.9 71.5% | 103.2 68.7% | 116.9 67.0% | 136.7 67.8% |
| Operating Expenses | 28.2 | 52.1 | 355.7 | 115.2 | 104.9 | 130.6 |
| Research & Development Expenses (R&D) | 4.1 | 6.3 | 153.4 | 17.2 | 19.9 | 26.7 |
| Selling, General & Administrative Expenses (SG&A) | 24.1 | 45.8 | 202.3 | 98.1 | 85.1 | 103.9 |
% margin | 13.9 23.5% | 6.1 7.6% | (275.9) (247.0%) | (12.0) (8.0%) | 11.9 6.8% | 6.2 3.1% |
| Interest Income | 0.7 | 1.7 | 4.6 | 0.4 | 0.0 | 1.7 |
| Interest Expense | 0.7 | 1.7 | 4.6 | 0.4 | 0.0 | 0.0 |
| Pre-tax Income | 13.1 | 4.5 | (281.7) | (12.2) | 11.5 | 7.4 |
% effective tax rate | 0.5 3.7% | 0.4 9.6% | 0.6 (0.2%) | 1.1 (8.8%) | 2.2 19.4% | 4.6 61.8% |
% margin | 12.7 21.4% | 4.1 5.1% | (282.2) (252.7%) | (13.3) (8.8%) | 6.0 3.5% | 2.8 1.4% |
| EPS | 0.11 | 0.04 | (4.30) | (0.16) | 0.10 | 0.02 |
| Diluted EPS | 0.11 | 0.04 | (4.30) | (0.16) | 0.07 | 0.01 |
% margin | 15.0 25.5% | 8.4 10.5% | (271.9) (243.4%) | (5.6) (3.7%) | 21.9 12.6% | 6.2 3.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Enfusion, Inc.'s EBITDA margin?
As of today, Microsoft Corp's last 12-month EBITDA margin is 7.2%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual EBITDA margin for Enfusion, Inc. have been (56.7%) over the past three years, and (36.5%) over the past five years.
2) Is Enfusion, Inc.'s EBITDA margin Good?
As of today, Enfusion, Inc.'s EBITDA margin is 7.2%, which is higher than industry median of 2.8%. It indicates that Enfusion, Inc.'s EBITDA margin is Good.